Dalteparin (subcutaneous)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Dalteparin (subcutaneous), covering 2020-01-06 to 2020-01-06. Get the full timeline:
Most recent: Clinical Trial Update: A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism [Phase 2]